Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients: Meta-analysis of Efficacy in Pivotal Randomized Controlled Trials

被引：0
|
作者：
Manier, Salomon [1 ]
Robinson, Suzanne [2 ]
Owen, Melody [3 ]
Dhanasiri, Sujith [2 ]
Frederickson, Andrew [3 ]
Jackson, Graham [4 ]
Facon, Thierry [1 ]
机构：
[1] CHU Lille, Dept Haematol, Lille, France
[2] Celgene Corp, Summit, NJ USA
[3] Precis Xtract, Oakland, CA USA
[4] NCCC Freeman Hosp, Clin Haematol, Newcastle Upon Tyne, Tyne & Wear, England
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
meta-analysis; Multiple myeloma;
D O I：
10.1016/j.clml.2019.09.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-012
引用
收藏
页码：E9 / E10
页数：2
相关论文
共 50 条
  • [41] The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
    Okazuka, Kiyoshi
    Ishida, Tadao
    Nashimoto, Junichiro
    Uto, Yui
    Sato, Kota
    Miyazaki, Kanji
    Ogura, Mizuki
    Yoshiki, Yumiko
    Abe, Yu
    Tsukada, Nobuhiro
    Suzuki, Kenshi
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (02) : 110 - 115
  • [42] Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Kharfan-Dabaja, Mohamed A.
    Hamadani, Mehdi
    Reljic, Tea
    Nishihori, Taiga
    Bensinger, William
    Djulbegovic, Benjamin
    Kumar, Ambuj
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6
  • [43] Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials
    Mohamed A Kharfan-Dabaja
    Mehdi Hamadani
    Tea Reljic
    Taiga Nishihori
    William Bensinger
    Benjamin Djulbegovic
    Ambuj Kumar
    Journal of Hematology & Oncology, 6
  • [44] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Twumasi-Ankrah, Philip
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    BLOOD, 2021, 137 (26) : 3616 - 3628
  • [45] STEM CELL MOBILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA FOLLOWING THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE
    Kumar, S.
    Lacy, M. Q.
    Dispenzieri, A.
    Hayman, S. R.
    Dingli, D.
    Miceli, T.
    Litzow, M. R.
    Rajkumar, S. V.
    Gertz, M. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 66 - 66
  • [46] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    BLOOD, 2018, 132
  • [47] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
    Dytfeld, Dominik
    Jasielec, Jagoda
    Griffith, Kent A.
    Lebovic, Daniel
    Vesole, David H.
    Jagannath, Sundar
    Al-Zoubi, Ammar
    Anderson, Tara
    Detweiler-Short, Kristen
    Stockerl-Goldstein, Keith
    Ahmed, Asra
    Jobkar, Terri
    Durecki, Diane E.
    McDonnell, Kathryn
    Mietzel, Melissa
    Couriel, Daniel
    Kaminski, Mark
    Vij, Ravi
    Jakubowiak, Andrzej J.
    HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
  • [48] Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high-risk cytogenetics: A meta-analysis of randomized controlled trials
    Chakraborty, Rajshekhar
    Siddiqi, Rabbia
    Wilson, Gloria
    Gupta, Samiksha
    Asghar, Noureen
    Husnain, Muhammad
    Aljama, Mohammed
    Behera, Tapas Ranjan
    Anwer, Faiz
    Perrot, Aurore
    Riaz, Irbaz B.
    CANCER, 2022, 128 (12) : 2288 - 2297
  • [49] Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials
    Wang, Long
    Xu, Yan-Li
    Zhang, Xiu-Qun
    LEUKEMIA & LYMPHOMA, 2014, 55 (07) : 1479 - 1488
  • [50] A 28 Day Schedule for Lenalidomide Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Chari, Ajai
    Roper, Nitin
    Jagannath, Sundar
    BLOOD, 2011, 118 (21) : 1272 - 1273
12345